국제백신연구소 (IVI)

We are one month away from the 23rd IVI International Vaccinology Course! General registration remains OPEN to attend in Seoul, Stockholm, or Kigali: https://lnkd.in/gjix7R_k Join us for five immersive days covering the basics of vaccinology and the process involved in creating vaccines—how they are developed, tested, regulated, and approved—while emphasizing their ultimate utility: vaccination.

We are pleased that EuBiologics has inked a contract with DEK Vaccines in Ghana to transfer manufacturing technology and supply raw materials for its oral cholera vaccine (Euvichol-S), which was developed in collaboration with IVI. The transfer of fill/finish is an important dissemination of this technology that lowers the cost while increasing the yield of oral cholera vaccine, which is in short supply globally. DEK is building a cholera vaccine fill and finish production facility with support from the European Investment Bank, and aims to launch the vaccine by the end of 2026. IVI is committed to supporting the development of regional vaccine manufacturing capabilities in Africa and boosting the global supply of OCV and other vaccines crucial for global health. https://lnkd.in/gE4QPMiY

Vaccines are estimated to save over 4 million lives annually, making them a cornerstone of public health, especially in low- and middle-income countries (LMICs). They not only protect us from infections but also play a crucial role in reducing the need for antibiotics, thus addressing antimicrobial resistance #AMR. The exact impact of #vaccines on AMR and their economic benefits need further exploration. 📢That is why the International Vaccine Institute (IVI) is excited to partner with The International Centre for Antimicrobial Resistance Solutions (ICARS)  to announce a joint Request for Proposal (RFP). We invite proposals from South and South-East Asian LMICs to develop strategies that highlight AMR as a key metric in vaccine investment cases. With a population of 2.4 billion in South Asia and 675 million in South-East Asia, the region faces a high burden of AMR. Robust immunization programs and a network of partners in vaccine research and development make these areas ideal for impactful projects. 🤝 Join us in creating a knowledge network of vaccine and AMR stakeholders to lead the charge in using vaccines to manage AMR! 🔗 Learn more and apply now: https://lnkd.in/e85_qcbw

Cholera remains a serious public health threat in Ethiopia, with over 15.9 million people (15% of the population) living in outbreak-prone areas. Outbreaks of cholera have struck annually in this region for the past nine years, with the current outbreak in its second year. In response, the Government of Ethiopia launched the National Cholera Elimination Plan (NCP): 2022–2028 which aims to achieve zero local transmission by 2028 and a 90% reduction in fatalities. This ambitious plan is a multisectoral approach to improving water, sanitation, and hygiene (WASH) services, disease surveillance and reporting, case management, oral cholera vaccine usage, and stakeholder engagement. IVI’s Ethiopia Cholera Control and Prevention team led by Dr. Se Eun Park and investigators from Armauer Hansen Research Institute and Ethiopia Public Health Institute share their findings, experiences, and strategies forward for the national plan in a collection of papers published in a new supplement for Clinical Infectious Diseases, published by Oxford University Press. Access the articles here: https://lnkd.in/gYKMgCy8

It's #WorldHepatitisDay and it's time to take action. In line with our mandate to accelerate vaccines for poverty-associated infectious diseases, IVI has been driving pivotal implementation research to make a hepatitis E vaccine more widely available, especially for those who are at highest risk for severe hepatitis E virus and related complications. Dr. Julia Lynch, Program Director at IVI, shares: “Although there is a safe and highly effective hepatitis E vaccine evaluated among healthy adults in China, the available data on the product is insufficient to support broader use. That’s what we’re trying to change by generating more information on the vaccine’s safety and immunogenicity in high-risk groups including pregnant women and immunosuppressed people, and in children. We hope to provide data to inform policy makers and support prequalification of the vaccine which will greatly expand accessibility.” Read more: https://lnkd.in/gtmPdwuW

It was a pleasure to host The Honourable Mélanie Joly, Canada’s Minister of Foreign Affairs, who made an official visit to our headquarters today to announce Canada's intention to join IVI as a State Party. Minister Joly’s visit, on which she was accompanied by H.E. Tamara Mawhinney, Ambassador of Canada to the Republic of Korea, and other departmental officials from Global Affairs Canada | Affaires mondiales Canada, follows a formal written request for Canada to join the IVI—which has since been approved by IVI's Board. We look forward to welcoming Canada and deepening our partnership with the government and R&D ecosystem to advance our shared goals for vaccine science and equitable global health. https://lnkd.in/gbuk4zGx

Registration is open for the 17th Asian Conference on Diarrhoeal Disease and Nutrition (ASCODD), hosted by Oxford University Clinical Research Unit Nepal (OUCRU Nepal), taking place in Kathmandu from 8-10 December 2024. This year’s conference theme is “Emerging Enteric Infections and Impact of Climate Change.”   📅 8-10 December 2024 | Kathmandu, Nepal 📝 Submit your abstracts by August 30, 2024   Find out more: www.ascodd2024.org

⏰ The deadline is fast approaching to apply for the 2024 Introductory Course for Standard Practice (GxP), offered by GTH-B. If you are a technician, engineer, or manager working in bioproduction at a facility based in a low- or middle-income country, learn more about this 3-week course on Good Clinical, Manufacturing, and Laboratory Practice and the basics of biosafety: https://lnkd.in/eCv_7pzG. Apply by July 19, 2024!

A new study led by IVI and collaborators published in The Lancet Global Health shows that Euvichol-S, a simplified oral cholera vaccine (OCV), is non-inferior to the first-generation OCV Shanchol™ in a Phase 3 trial conducted in Nepal. Based on the results of this study, Euvichol-S achieved World Health Organization prequalification earlier this year, paving the way for its global use in endemic and outbreak settings. Learn more: https://lnkd.in/g9jzJmD3

"Although a sore throat is often what comes to mind when people think of a Strep A infection, Streptococcal toxic shock syndrome (STSS) is a different iteration of the disease, caused by the same bacterial species." https://lnkd.in/gHK4NJ_7 In this article from the Washington Post, Prof. Andrew Steer, Co-Chair of the SAVAC Executive Committee, shares the fatal potential of Group A Streptococcus bacteria and the rise of STSS cases around the world. The article notes that there is not yet a vaccine for Group A Strep infections, but Prof. Steer, IVI Director General Dr. Jerome Kim, and the SAVAC consortium are at work to change that. On the sidelines of World Vaccine Congress in Washington this year, SAVAC held an industry forum focusing on catalyzing industry investment in Strep A vaccine R&D. Read the report here: https://lnkd.in/gf77Rmj4